Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Bicycle Therapeutics (BCYC) to $17 from $15 and keeps an Equal Weight rating on the shares. Following Bicycle’s Q1 earnings announcement, the firm awaits greater visibility on the timing of Duravelo-2 response data and clarity on the pipeline prioritization, which it believes “could support upside realization.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics: Strong Pipeline Progress and Strategic Expansion Support Buy Rating
- Bicycle Therapeutics price target lowered to $14 from $17 at B. Riley
- Bicycle Therapeutics price target lowered to $22 from $26 at Citizens JMP
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays